Newark, New Jersey — A significant rise in cases of Respiratory Syncytial Virus (RSV), a highly contagious respiratory illness, is impacting communities across the United States, with notable increases in New Jersey. The Centers for Disease Control and Prevention (CDC) has reported elevated RSV activity, highlighting that this common virus primarily causes mild, cold-like symptoms in most individuals. However, it poses severe risks for vulnerable populations, including infants, the elderly, and those with weakened immune systems.

RSV typically begins to circulate in the fall, peaking during winter months. In New Jersey, emergency room visits related to RSV have surged since early October, with more than half of the state’s counties experiencing “high” or “very high” levels of emergency visits for the virus. The current outbreak coincides with widespread respiratory illnesses, raising alarm among health officials.

Nationwide, RSV accounts for approximately 0.5 percent of all emergency department visits, with New Jersey reporting slightly higher rates at 0.7 percent. As of late January, the state has recorded over 300 hospitalizations attributed to RSV, predominantly affecting children under age 4 and adults over 65. Each year, an estimated 2 to 3 percent of infants under six months are hospitalized with RSV infections, emphasizing the gravity of the situation for this demographic.

While most children recover from RSV with mild symptoms, those born prematurely or who have certain medical conditions are at higher risk for complications. Statistics show that RSV contributes to the deaths of between 100 and 300 children annually. This underscores the importance of protective measures for the most vulnerable individuals.

To mitigate the impact of severe RSV, the CDC recommends vaccination strategies for pregnant women and provides options for prophylactic treatments for infants. Health officials emphasize the availability of monoclonal antibody therapies, such as clesrovimab and nirsevimab, designed to prevent severe RSV disease in young children, particularly those under eight months who are navigating their first RSV season.

Public health authorities also advise vaccination for specific high-risk groups, including adults aged 50 to 74 with chronic heart or lung conditions, as well as all individuals aged 75 and older. According to recent data, one dose of the RSV vaccine offers protection for at least two years. However, vaccination coverage remains a concern, with only 43.4 percent of adults aged 75 and older and 30.6 percent of those aged 50 to 74 receiving the vaccine by the end of December 2025.

As RSV continues to challenge the healthcare system, experts urge community members to remain vigilant, practice good hygiene, and take preventive measures to protect themselves and those at risk. Enhanced awareness and vaccination efforts are critical as RSV season progresses, aiming to reduce the strain on hospitals and protect vulnerable populations.